UPC NASDAQ
Universe Pharmaceuticals Inc.
1W: -5.3%
1M: -5.7%
3M: -25.0%
YTD: +8.2%
1Y: +2.3%
3Y: -99.2%
5Y: -100.0%
$4.50
+0.19 (+4.41%)
Weekly Expected Move ±12.3%
$3
$4
$4
$5
$6
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$18M
-22.4% ▼
5Y CAGR: -10.3%
Gross Profit
$6M
+3.8% ▲
5Y CAGR: -14.9%
Operating Income
-$3M
+63.6% ▲
Net Income
-$4M
+57.9% ▲
EPS (Diluted)
$-1055.75
+26.5% ▲
EBITDA
-$3M
+60.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $48M | $40M | $32M | $23M | $18M |
| YoY Growth | +56.3% | -16.3% | -19.5% | -28.7% | -22.4% |
| Cost of Revenue | $23M | $18M | $22M | $17M | $12M |
| Gross Profit | $25M | $22M | $10M | $6M | $6M |
| Gross Margin | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% |
| R&D Expenses | $5M | $8M | $5M | $3M | $672K |
| SG&A Expenses | $6M | $21M | $9M | $10M | $8M |
| Operating Expenses | $12M | $29M | $14M | $14M | $9M |
| Operating Income | $14M | -$7M | -$4M | -$8M | -$3M |
| Operating Margin | 28.3% | -17.5% | -10.9% | -34.8% | -16.3% |
| Interest Expense | $102K | $162K | $157K | $278K | $232K |
| Income Before Tax | $14M | -$8M | -$4M | -$8M | -$4M |
| Tax Expense | $2M | $752K | $2M | $607K | $0 |
| Net Income | $11M | -$9M | -$6M | -$9M | -$4M |
| Net Margin | 23.6% | -21.8% | -19.1% | -37.9% | -20.6% |
| EPS (Diluted) | $2147.18 | $-1475.02 | $-1040.53 | $-1436.12 | $-1055.75 |
| EBITDA | $14M | -$6M | -$3M | -$7M | -$3M |
| Shares Outstanding | 5272 | 5923 | 5923 | 6077 | 3478 |